This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Law and Medicine  • Violence and Human Rights  • Bioterrorism  • Alert me on articles by topic  Social Bookmarking   What's this?

Brian Vastag

JAMA. 2003;290:590.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The House of Representatives voted to approve $5.6 billion for Project Bioshield, an initiative designed to spur development of treatments for bioterrorism pathogens. The initiative includes three components: guaranteed government purchase of new diagnostic tests and treatments; new National Institutes of Health authority to speed research; and provisions to allow the widespread use of vaccines and treatments before formal US Food and Drug Administration (FDA) approval.

A clinician demonstrates how to administer the currently available smallpox vaccine; efforts are under way to develop a safer vaccine. In July, the US House of Representatives approved $5.6 billion to spur development of new vaccines and treatments against potential bioterror agents. (Photo credit: James Gathany/CDC)

At Congressional hearings this spring, representatives from biotechnology companies testified that the ultimate effectiveness of the project depends on long-term, consistent funding. Una Ryan, PhD, president of AVANT Immunotherapeutics, Needham, Mass, told Congress that because new . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?